author-photo

Rodrigo Santucci Silva

18

Papers

638

Citations

Citation Trend

Filter By

Papers (12) Sort By

Journal Conference Others

Final 5-year findings from the phase 3 HELIOS study of ibrutinib plus bendamustine and rituximab in patients with relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma.

2020 Leukemia & Lymphoma
Show All
- Source
- Cite
- Save
Citations (8)
Pharmacoeconomic Analysis of the Real World Treatment of Chronic Myeloid Leukemia in Chronic Phase of a Brazilian Private Institution Considering the Use of Generic Drugs and Eventual Discontinuation of Treatment

2019 Blood
Show All
- Source
- Cite
- Save
Citations (0)
Ibrutinib Maintenance after Chemoimmunotherapy Is Feasible and Results in Excellent Progression-Free and Overall Survival in Patients with Detectable MRD after Chemoimmunotherapy

2019 Blood
Show All
- Source
- Cite
- Save
Citations (0)
A Randomized, Double-Blind Efficacy and Safety Study of PF-05280586 (a Potential Rituximab Biosimilar) Compared with Rituximab Reference Product (MabThera Â® ) in Subjects with Previously Untreated CD20-Positive, Low Tumor Burden Follicular Lymphoma (LTB-FL)

2018 Blood
Show All
- Source
- Cite
- Save
Citations (4)
Ibrutinib versus temsirolimus in patients with relapsed or refractory mantle-cell lymphoma: an international, randomised, open-label, phase 3 study

2016 The Lancet
Show All
- Source
- Cite
- Save
Citations (273)
Ibrutinib (I) plus bendamustine and rituximab (BR) in previously treated chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL): a 2-year follow-up of the HELIOS study.

2016 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (8)
Insights into the Management of Adverse Events in Patients with Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma: Experience from the Phase 3 HELIOS Study of Ibrutinib Combined with Bendamustine/Rituximab

2015 Blood
Show All
- Source
- Cite
- Save
Citations (3)
Ibrutinib combined with bendamustine/rituximab (BR) in previously treated chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL): subgroup efficacy analyses from the HELIOS trial

2015 Leukemia & Lymphoma
Show All
- Source
- Cite
- Save
Citations (1)
Ibrutinib Plus Bendamustine/Rituximab (BR) Is Associated with Greater Reductions in Fatigue Than Placebo Plus BR Among Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia and Fatigue

2015 Blood
Show All
- Source
- Cite
- Save
Citations (0)
Improvement of Quality of Response with Ibrutinib Plus Bendamustine/Rituximab Vs Placebo Plus Bendamustine/Rituximab for Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)

2015 Blood
Show All
- Source
- Cite
- Save
Citations (1)